---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-014016"
form_type: "8-K"
ticker: "ZOMDF"
cik: "0001684144"
company_name: "Zomedica Corp."
filed_at: "2024-11-08T23:59:59+00:00"
generated_at: "2026-05-30T02:52:32.840418+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Zomedica Q3 revenue up 10% to $7.0M; gross margin 72.3%; diagnostics segment grows 38%

## Summary
- Revenue $7.0M (+10% YoY); gross margin 72.3% above 65-70% guidance.
- Diagnostics segment revenue $0.5M (+38% YoY); Therapeutic Device $6.5M (+9%).
- Net loss $6.7M vs $0.5M loss a year ago (prior year included $2.2M acquisition gain).
- Adjusted non-GAAP EBITDA loss $4.3M; operating cash burn ~$5.2M, adjusted $4.0M.
- Cash & securities $77.8M at Sept 30, down from $83.0M at June 30; no guidance change.

## SEC filing metadata
- accession: 0001654954-24-014016
- form_type: 8-K
- ticker: ZOMDF
- cik: 0001684144
- company_name: Zomedica Corp.
- filed_at: 2024-11-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1684144/000165495424014016/0001654954-24-014016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1684144/000165495424014016/zom_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-014016
- JSON: https://secwatch.observer/filing/0001654954-24-014016.json
- Plain text: https://secwatch.observer/filing/0001654954-24-014016.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.